FierceBiotech

Nevro's high-frequency neurostimulation cuts diabetic neuropathy pain by 80% in 2-year study

Two years after a high-frequency version of Nevro’s neurostimulation system became the first spinal cord stimulator approved by the FDA with a specific indication to treat pain associated with ...
Business Insider

Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Next Generation Senza ® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., Oct. 12, ...
CNN

Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
FierceBiotech

Nevro nabs FDA approval for spinal cord stimulator that uses AI to personalize pain treatment

Most neurostimulation devices can be manually adjusted by users and their caregivers to customize treatments for chronic pain, epilepsy, stroke recovery and more, but an implant newly approved by the ...
Becker's ASC

Nevro Receives FDA Approval to Test Spinal Cord Stimulation Device

Nevro yesterday announced that the FDA has granted approval for a study evaluating its high-frequency spinal cord stimulation system for the treatment of chronic pain. The device company’s Senza ...
WDAF-TV

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...